Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.
about
Low dose naltrexone for induction of remission in Crohn's diseaseLow dose naltrexone for induction of remission in Crohn's diseaseThe Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A ReviewOverview and treatment of opioid-induced constipation.Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signalingActivation of μ opioid receptors modulates inflammation in acute experimental colitis.micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study.Protective role of μ opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice.Nuclear factor kappaB signaling in opioid functions and receptor gene expressionOpioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections.Role of neuropeptides in inflammatory bowel disease.Opioids and clonidine modulate cytokine production and opioid receptor expression in neonatal immune cells.Effects of methylnaltrexone on guinea pig gastrointestinal motility.Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in micePhysiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications.The putative role of endogenous and exogenous opiates in inflammatory bowel disease.Release of endogenous opioids from duodenal enteroendocrine cells requires Trpm5Insights into the Role of Opioid Receptors in the GI Tract: Experimental Evidence and Therapeutic Relevance.Targeting opioid signaling in Crohn's disease: new therapeutic pathways.Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus.The opioid antagonist naltrexone improves murine inflammatory bowel disease.Mu and delta opioid receptor knockout mice show increased colonic sensitivity.Systemic Administration of Sialorphin Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors.Alteration of neuromuscular transmissions in the hamster colon following the resolution of TNBS-induced colitis.CO-EXPRESSION OF μ AND ∂ OPIOID RECEPTORS BY MOUSE COLONIC NOCICEPTORS.Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.Attenuating the Agent: Reducing Opioid “Virulence”
P2860
Q24200319-1184EF4A-22F2-4798-BD2C-F7255C8A90F8Q24201218-57C2D1FA-C62B-423C-8D0F-EAD0513D9980Q26851158-BA6A4A3A-8D25-4D42-909A-4C3C88C3EAF3Q34352001-4485DCE6-8E24-41D2-B746-542D94C67992Q35168195-221AD882-7C29-48AD-8BFF-538B35A21B36Q35510067-D660E19E-D5FD-440C-B90E-8406957C7A82Q36014007-6AF72563-C057-42A0-A3F2-5A7BD100D223Q36185519-05359ED8-2C77-4C96-8CD9-1864952324F7Q36227327-76F88E5F-3FD7-437E-81E1-887F8339F9B7Q36245077-D56EA479-D0B6-471F-9DF7-6AED53989FD5Q36694953-43EE2C48-FC29-4E9E-93E3-51091BA354BEQ36753635-CF4ADD41-54FB-44AE-A7C6-113278E914A3Q36807974-87E4CE3B-3FAC-4F5F-AFD1-5B643780E32AQ36854395-17E65DAA-E133-43CD-8FD5-6DF148F8BB3BQ37340687-F17652BD-CA3C-45B4-B55A-DC0DA47AB5D2Q37491434-8000423B-564F-4E3B-ADF0-41D95808C7EDQ38618026-9A3BED47-1DF2-4A52-84A2-553CE061D27AQ38911748-AEF130DB-E400-403B-A4C6-575E654EEC44Q41763894-6DDBBF6C-82EF-4851-87AE-DCADD279D259Q42044354-A344A283-BDB2-423D-B25B-0DEF2613002CQ43062074-EF7D5C93-282A-4AF0-B9DA-3D43C54B8E42Q44330585-6052A3CB-09CC-4635-AE7A-8EDED00734A1Q44337813-BF8685D5-20A8-4CF2-988C-6863B04216D8Q44339195-DE62E25B-3D21-4CBC-87D6-C880B317BF7FQ44340786-7C9A1A12-711D-49A0-8B39-04C7520B8401Q44344238-F192D739-F203-45DD-BEA2-3022F26E1ED5Q51753894-04CC23A6-C1C6-49B0-8C2C-0263AD28B643Q52630975-A76D54DB-EFE9-4864-BCA1-9DD57777F0EBQ52664057-3D26FA0F-6767-46CF-A6D0-35FBC9A484CCQ57462886-FAF719CE-B68A-4B0D-B5E5-A56F83EDACD5
P2860
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mu opioid receptor expression ...... tatic intestinal inflammation.
@ast
Mu opioid receptor expression ...... tatic intestinal inflammation.
@en
type
label
Mu opioid receptor expression ...... tatic intestinal inflammation.
@ast
Mu opioid receptor expression ...... tatic intestinal inflammation.
@en
prefLabel
Mu opioid receptor expression ...... tatic intestinal inflammation.
@ast
Mu opioid receptor expression ...... tatic intestinal inflammation.
@en
P2093
P2860
P50
P356
P1433
P1476
Mu opioid receptor expression ...... static intestinal inflammation
@en
P2093
D Philippe
J-F Colombel
M Chamaillard
P2860
P304
P356
10.1136/GUT.2005.080887
P407
P577
2005-11-18T00:00:00Z